Effect of Moxifloxacin plus Pretomanid against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay

Combination therapy is a successful approach to treat tuberculosis in patients with susceptible strains of Mycobacterium tuberculosis. However, the emergence of resistant strains requires identification of new, effective therapies. Pretomanid (PA824) and moxifloxacin (MXF) are promising options curr...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Antimicrob Agents Chemother
Päätekijät: de Miranda Silva, Carolina, Hajihosseini, Amirhossein, Myrick, Jenny, Nole, Jocelyn, Louie, Arnold, Schmidt, Stephan, Drusano, George L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2018
Aiheet:
Experimental Therapeutics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6325209/
https://ncbi.nlm.nih.gov/pubmed/30397058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01695-18
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia